Boston Scientific’s Deep Brain Stimulation System

Therapy without compromise

Tailor a DBS system specific to your workflow and each of your patients’ needs. With five MR-Conditional* implantable pulse generators (IPGs), the most therapy options** and Image Guided Programming, Vercise Genus™ Deep Brain Stimulation System enables you to personalize DBS therapy as unique as each one of your patients.

To get answers to your questions and additional information, contact a DBS sales representative.

Vercise Genus Deep Brain Stimulation System

Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system.

See product details

Boston Scientific's Deep Brain Stimulation system, including tablet with Vercise Neural Navigator 5 Software, five recharable and chargable IPGs, and wireless remote.

5 thin, contoured ImageReady™  MR-Conditional rechargeable and  non-rechargeable IPGs

15 year warranty* on our rechargeable IPGs

The most therapy options including Semi-bipolar and Anodic stimulation

Personalize therapy with Image Guided Programming

Vercise™ Neural Navigator 5 Software with Image Guided Programming

Vercise Neural Navigator 5 Software makes it easier and more efficient to personalize your patients’ DBS journey.

Learn more about Vercise Neural Navigator 5

Tablet with Vercise Neural Navigator 5 Software showing brain stimulation programming options and IPG information for a specific patient.

Gloved hands hold the Vercise Genus P8 IPG, the first and only directional 8-contact, single-channel IPG with 4- to 7-year battery longevity.

Vercise Genus™ Battery Portfolio

Choose from five small, contoured rechargeable and non-rechargeable MR-Conditional IPGs designed for patient comfort and convenience.

Rechargeable options provide 30 days of stimulation between recharging cycles², while non-rechargeable options include the Vercise™ P8 Battery—the only directional single channel primary cell in the market.

Explore the most comprehensive suite of options

Clinical data

The Vercise™ DBS Systems are supported by dozens of studies with hundreds of patients showing clinical benefits to patients globally.

Explore key study findings

56.4%

improvement in motor function (MDS-UPDRS III)³

Stay up to date

Receive emails about the latest DBS advances, clinical data and product news.

An ImageReady™ MR-Conditional System

Learn how the ImageReady MR-Conditional DBS System allows patients to safely undergo MRI scans.

Learn more about the system

Reimbursement resources

Find Vercise Genus DBS System procedural coding and reimbursement information for inpatient, outpatient, office and ASC codes.

See reimbursement resources

If you are a patient looking for more information on DBS, visit DBSandMe.com.

*MR-Conditional when all conditions of use are met.
**Information for competitive devices excerpted from the literature published by Medtronic (M982261A015 Rev A, M939241A051 Rev A, M013074C001 Rev B, M982097A013 Rev A, M13075C001 Rev B, M019192C002 Rev A) and Abbott (ARTEN600150429 - B, ARTEN600102238 - A, ARTEN600266398 -A, ARTEN600308953 -A, ARTEN600308947 -A), and Schüpbach, Michael & Chabardes, Stephan & Matthies, Cordula & Pollo, Claudio & Steigerwald, Frank & Timmermann, Lars & Vandewalle, Veerle & Volkmann, Jens & Schuurman, P.. (2017). Directional leads for deep brain stimulation: Opportunities and challenges. Movement Disorders. 32. 10.1002/mds.27096. Steffen, J. K., Reker, P., Mennicken, F. K., Dembek, T. A., Dafsari, H. S., Fink, G. R., Visser-Vandewalle, V., & Barbe, M. T. (2020). Bipolar Directional Deep Brain Stimulation in Essential and Parkinsonian Tremor. Neuromodulation: Technology at the Neural Interface, 23(4), 543–549. DOI: 10.1111/ner.13109 Reker, P., Dembek, T. A., Becker, J., Visser-Vandewalle, V., & Timmermann, L. (2016). Directional deep brain stimulation: A case of avoiding dysarthria with bipolar directional current steering. Parkinsonism & Related Disorders, 31, 156-158. https://doi.org/10.1016/j.parkreldis.2016.08.007 Kirsch, A. D., Hassin-Baer, S., Matthies, C., Volkmann, J., & Steigerwald, F. (2018). Anodic versus cathodic neurostimulation of the subthalamic nucleus: A randomized-controlled study of acute clinical effects. Parkinsonism & Related Disorders, 55, 61-67. https://doi.org/10.1016/j.parkreldis.2018.05.015. Boston Scientific (Vercise ™ Neural Navigator 5 Software Programming Manual MP92736308-01)
†STIMVIEW™ XT Technology is a visual representation of the estimated stimulation field.

REFERENCES:

Image Guided programming in PD patients enables a reduction in programming time compared with standard clinical based programming (p=39). Lange F, Et al. Reduced Programming Time and Strong Symptom Control Even in Chronic Course Through Imaging-Based DBS Programming. Front Neurol. 2021 Nov 8;12:785529. N=10
Yu et al. (2013). “Characterizing Rechargeable IPG Charge Cycle Time in DBS.” NANS 2013 Poster.
2023. Real-World Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control - US Experience. North American Neuromodulation Society, January 2023, Las Vegas, NV. (N = 49)

A System that includes the Vercise™ PC, Vercise Gevia™, or Vercise Genus™ IPG and Vercise Cartesia™ Directional Lead(s) forms the Vercise Directional System

The Vercise Genus™ DBS System, Vercise Genus Mixed System with Vercise™ M8 Adapter, Vercise Genus Mixed System with Vercise™ Adapter S8, Vercise Gevia™ DBS System, and Vercise™ DBS Lead-only system (before Stimulator is implanted) provide safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under specific conditions defined in the supplemental manual ImageReady™ MRI Guidelines for Boston Scientific DBS Systems.

INDICATION FOR USE:
The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:

Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.
Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability.

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:

Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, SIDE EFFECTS:
The Boston Scientific Deep Brain Stimulation (DBS) Systems or any of its components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific DBS System without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Boston Scientific DBS Systems or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

My account